XML 63 R49.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Research and License Agreements - Additional Information (Detail) |  |  | 1 Months Ended | 12 Months Ended | 27 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2011 USD ($) item | Feb. 29, 2004 | Aug. 31, 2015 USD ($) | Jun. 30, 2015 USD ($) | May 31, 2014 USD ($) | Oct. 31, 2011 USD ($) item | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2013 | Feb. 29, 2016 USD ($) | Dec. 31, 2015 USD ($)
License Agreement |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Non-cash consideration received |  |  |  |  |  |  | $ 0 |  |  |  |
Consideration paid |  |  |  |  |  |  | 0 |  |  |  |
License Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Milestone revenue |  |  | $ 20,000,000 |  |  |  | 0 | $ 0 |  |  |
Transaction price |  |  |  |  |  | $ 22,500,000 |  |  |  |  |
Number of milestones included in transaction price | item |  |  |  |  |  | 0 |  |  |  |  |
License Agreement | Pfizer | Up-Front Payment Arrangement |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 22,500,000 |  |  |  |  |  |  |  |  |  |
Recognition period of up-front payment |  |  |  |  |  |  |  |  | 1 year 6 months |  |
Research Services Agreement | University Of Basel |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Royalty payment due against license fees received (as a percent) |  | 10.00% |  |  |  |  |  |  |  |  |
Milestone license fee liability |  |  |  |  |  |  |  |  |  | $ 2,000,000 | $ 2,000,000
Milestone payment obligation |  |  |  |  |  |  | $ 0 | $ 0 |  |  |
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 115,000,000 |  |  |  |  |  |  |  |  |  |
Number of indications | item | 2 |  |  |  |  |  |  |  |  |  |
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 70,000,000 |  |  |  |  |  |  |  |  |  |
Number of indications | item | 2 |  |  |  |  |  |  |  |  |  |
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 135,000,000 |  |  |  |  |  |  |  |  |  |
Achievement Of Dosing First Patient In Clinical Trial | License Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |
Milestone revenue |  |  |  | $ 20,000,000 | $ 15,000,000 |  |  |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for license and milestone fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | glyc_AccruedLicenseAndMilestoneFees
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | glyc_ArrangementsAndNonarrangementTransactionsLineItems
Namespace Prefix: | glyc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration paid to counterparty as part of the arrangement in the evaluation of the agreement under ASC 606. + References No definition available. + Details
Name: | glyc_ConsiderationPaid
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of non-cash consideration received in the evaluation of the agreement under ASC 606. + References No definition available. + Details
Name: | glyc_NonCashConsiderationReceived
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of clinical or regulatory milestones included in the transaction price of the agreement. + References No definition available. + Details
Name: | glyc_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix: | glyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of indications that trigger payment of milestones under the agreement. + References No definition available. + Details
Name: | glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement
Namespace Prefix: | glyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the potential payment that may be received upon achievement of specified milestones per agreement. + References No definition available. + Details
Name: | glyc_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the royalty commitment due as a percent of the milestone payments received under licensing arrangement. + References No definition available. + Details
Name: | glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent
Namespace Prefix: | glyc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration determined to be the transaction price under the agreement recognized under ASC 606. + References No definition available. + Details
Name: | glyc_TransactionPrice
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period of time over which the up-front payment received was recognized as revenue. + References No definition available. + Details
Name: | glyc_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | glyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=glyc_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=glyc_UniversityOfBaselMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfDosingFirstPatientInClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |